BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount?
- BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation, tax credit, research, amount of $330.75K in Q4 2025.
- How has BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount changed year-over-year?
- BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount decreased by 25.0% year-over-year, from $441K to $330.75K.
- What is the long-term trend for BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount has grown at a -31.5% compound annual growth rate (CAGR), from $5.99M to $1.32M.
- What does effective income tax rate reconciliation, tax credit, research, amount mean?
- The dollar value of tax credits claimed for qualified research and development activities, which reduces the company's overall income tax expense. This metric is a key indicator of the company's investment in innovation and its ability to leverage government incentives.